Mendus AB (publ)
STO: IMMU.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Erik Manting
- Employees
- 28
- Headquarters
- Stockholm, Sweden
- IPO year
- 2013
- Market cap
- SEK 260.9M
- Website
- https://www.mendus.com
Loading IMMU…
Loading profile data…Frequently asked questions about IMMU
What does Mendus AB (publ) (IMMU.ST) do?
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products a...
Where does IMMU.ST trade?
Mendus AB (publ) (IMMU.ST) trades on the Stockholm Stock Exchange.
What sector is IMMU.ST in?
Mendus AB (publ) (IMMU.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mendus AB (publ)?
Erik Manting is the chief executive officer of Mendus AB (publ) (IMMU.ST).
Where is Mendus AB (publ) headquartered?
Mendus AB (publ) is headquartered in Sweden.
Does IMMU.ST pay a dividend?
Mendus AB (publ) (IMMU.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMMU.ST go public?
Mendus AB (publ) (IMMU.ST) completed its initial public offering in 2013.